# Pinealon (EDR): Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on Pinealon (Glu-Asp-Arg / EDR), the Khavinson ultrashort neuroprotective tripeptide. Reproducible preclinical antioxidant data, no human RCT, and an unapproved 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Pinealon (Glu-Asp-Arg, the "EDR" tripeptide) has a coherent, reproducible *preclinical* antioxidant-neuroprotection story — but **no human randomized controlled trial exists**, no ClinicalTrials.gov registration, and no Western replication. Its highest evidence grade is **C (preclinical only)**; human cognition and anti-aging claims grade **D**. It is not FDA-approved, is sold for research use only, and falls under WADA class S0 for athletes.[1](https://peptidevox.com/#r1)[6](https://peptidevox.com/#r6)

Pinealon is a synthetic ultrashort tripeptide — glutamic acid, aspartic acid, arginine (Glu-Asp-Arg; one-letter EDR) — from Vladimir Khavinson's St. Petersburg short-peptide or "bioregulator/cytogen" program, marketed for neuroprotection, cognition and longevity.[1](https://peptidevox.com/#r1) Its popularity in nootropic circles is real; its proof in humans is not. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Pinealon is not an FDA-approved drug; it is sold as a "research chemical not for human use" and falls under WADA's non-approved-substance class. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is Pinealon and how does it work?

Pinealon is a synthetic linear tripeptide, H-Glu-Asp-Arg-OH, CAS 175175-23-2, molecular formula C15H26N6O8, molecular weight about 418.4 g/mol.[5](https://peptidevox.com/#r5) It belongs to Khavinson's cytogen short-peptide family — ultrashort two-to-four amino acid peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology and proposed to act as tissue-specific gene regulators.[4](https://peptidevox.com/#r4) The "pinealon" name reflects a proposed neuroendocrine target, not its source; the EDR motif is described as derived from the cortical polypeptide preparation Cortexin.[1](https://peptidevox.com/#r1)

The distinguishing — and least-verified — claim is the mechanism. Unlike receptor-ligand peptides, EDR is proposed to enter cells, reach the nucleus and bind DNA at specific short sequences, thereby modulating transcription of neuroprotective genes. Molecular-modeling work reports EDR docking to hexanucleotide sites such as d(CCTGCC) and d(CCAGC) in the promoter regions of genes including SOD2, GPX1, PPARA, PPARG, CASP3, NES, GAP43 and APOE.[1](https://peptidevox.com/#r1) This DNA-binding, gene-targeting model is largely in silico plus single-group experimental support and has not been independently confirmed; the published reviews on PubMed Central frame it as a hypothesis rather than established pharmacology, and it should be read that way (see the open-access review at [PMC7795577](https://pmc.ncbi.nlm.nih.gov/articles/PMC7795577/)).[1](https://peptidevox.com/#r1) Downstream, in rat cerebellar granule cells EDR delayed homocysteine-induced ERK1/2 activation and showed an inhibitory effect on the MAPK/ERK pathway alongside ROS suppression.[2](https://peptidevox.com/#r2) No formal human pharmacokinetic data — Cmax, half-life, bioavailability — have been published; treat all PK statements as unverified.[1](https://peptidevox.com/#r1)

## What is the evidence by indication?

The reproducible signal is in vitro and in rodents; there is no human efficacy trial for any indication. Every row below is therefore best understood as preclinical evidence, graded C — except the human cognition observation, which grades D.

  Pinealon (EDR) evidence by indication

    IndicationBest evidenceGrade

    Neuroprotection / antioxidant defenseDose-dependent ROS suppression in cerebellar granule cells, neutrophils & PC12 cells; SOD2/GPX1 restoration in rodent hypoxiaC (preclinical)
    Prenatal hyperhomocysteinemia (developmental)Methionine-loading rat model: improved offspring spatial learning, reduced ROS & necrosisC (preclinical)
    Alzheimer's-type pathology5xFAD mouse hippocampal neurons: preserved mushroom-shaped dendritic spines under amyloidC (preclinical)
    Cognition in aging rodentsReduced brain caspase-3; improved Morris-water-maze learning in young & old ratsC (preclinical)
    Human cognition / TBI cerebrasthenia / anti-agingOne small, open, single-group clinical observation reported via review channelsD (no controlled evidence)

The antioxidant-neuroprotection evidence is the strongest. In the foundational study, Pinealon dose-dependently restricted ROS accumulation in rat cerebellar granule cells, peripheral-blood neutrophils and PC12 cells under oxidative stress from receptor-dependent agents (ouabain, homocysteine) and non-receptor agents (hydrogen peroxide), and reduced necrotic cell death.[2](https://peptidevox.com/#r2) In rodent hypoxia models, EDR restored brain SOD2 and GPX1 activity toward hypoxia-resistant levels, reduced hydroperoxides and prevented caspase-3 activation in neurons.[1](https://peptidevox.com/#r1) In a methionine-loading rat model of prenatal hyperhomocysteinemia, maternal Pinealon improved offspring spatial learning and reduced ROS and necrotic cell counts — notably without lowering offspring homocysteine, implying a downstream protective rather than metabolic effect.[3](https://peptidevox.com/#r3)

The human evidence is weak. The most-cited datapoint is an uncontrolled clinical observation in patients with traumatic-brain-injury sequelae and cerebrasthenia, in which oral Pinealon added to standard therapy was reported to improve memory and emotional balance, reduce headache burden and lower error rates.[1](https://peptidevox.com/#r1) This is not a randomized controlled trial: it is small, open, single-group and reported chiefly through review channels — so human cognitive benefit is unproven, Grade D. Broad longevity claims rest on the wider Khavinson program (animal lifespan plus non-blinded Russian clinical data), not on Pinealon human trials.[4](https://peptidevox.com/#r4)

Proven vs hyped
Proven: cell and rodent antioxidant-neuroprotection (Grade C). Hyped: human cognition, Alzheimer's benefit and "anti-aging," which rest on small uncontrolled observations and class-level extrapolation. There is no RCT, no Western replication, no ClinicalTrials.gov registration, and no FDA evaluation.[1](https://peptidevox.com/#r1)

## What doses appear in the literature?

Reported strictly as information, not a protocol. No validated human dose, frequency, route or safe upper limit has been established.[1](https://peptidevox.com/#r1) In cell culture, effects appear at nanomolar concentrations — roughly 1 to 100 nanomolar — with dendritic-spine rescue reported around 200 nanograms per milliliter.[2](https://peptidevox.com/#r2) Rodent studies use low microgram-per-kilogram parenteral or oral dosing across short courses, with specifics varying by model.[3](https://peptidevox.com/#r3) The single uncontrolled human observation in TBI cerebrasthenia cited oral Pinealon at about 0.2 milligrams twice daily for 20 to 30 days alongside standard therapy; the Khavinson class is typically used as short 10-to-30-day courses.[1](https://peptidevox.com/#r1) Pinealon is sold as a lyophilized research-use-only powder, and vendor reconstitution protocols are not derived from controlled human trials — they are excluded here as non-evidentiary.[4](https://peptidevox.com/#r4)

## How safe is Pinealon?

There is no formal human safety dataset of any quality: no published adverse-event profile, no toxicology dossier in the FDA or EMA sense, and no long-term human data for Pinealon specifically.[4](https://peptidevox.com/#r4) The broader Khavinson short-peptide class is described anecdotally and in program reports as well tolerated in short courses with no serious adverse events flagged, but this comes from the originating group and non-blinded Russian clinical use — low-quality evidence for safety.[4](https://peptidevox.com/#r4) Because the proposed mechanism is gene-expression modulation and stimulation of cell proliferation, an unquantified theoretical concern is proliferative or oncologic signaling — though the class is conversely reported to suppress tumorigenesis in rodents; both directions are preclinical and unsettled.[1](https://peptidevox.com/#r1) No human drug interactions are characterized. Precautionary contraindications include pregnancy and lactation, children and people with active malignancy. The largest practical hazard is product quality: research-use-only powders are unregulated for human use, with no guaranteed identity, purity, sterility or endotoxin content.[4](https://peptidevox.com/#r4)

## What is the FDA and WADA status in 2026?

Pinealon is not FDA-approved for any indication and has no recognized off-label use, since off-label status applies only to approved drugs. It is not a permitted compounding bulk substance — it is treated as effectively Category 2 and is not on the 503A interim list, so it cannot be lawfully compounded by 503A pharmacies or 503B outsourcing facilities for clinical use.[7](https://peptidevox.com/#r7) It is sold for research use only and not for human consumption, and marketing it with therapeutic claims (cognition, anti-aging, neuroplasticity) renders it an unapproved new drug; FDA enforcement attention to this class has been reported through 2025 into 2026.[8](https://peptidevox.com/#r8) It is not a DEA-controlled substance. Registered Khavinson pharmaceuticals such as Cortexin and Thymalin exist in Russia, but Pinealon itself is not an approved medicine in the US or EU.[4](https://peptidevox.com/#r4)

For athletes the picture is one of regulatory exclusion. Pinealon is not listed by name on the WADA Prohibited List, but as a substance not approved for human therapeutic use by any government regulator, it falls under WADA class S0 (non-approved substances), which captures research-only and unapproved peptides — meaning it should be treated as prohibited in sport at all times.[6](https://peptidevox.com/#r6) Any WADA-tested athlete should treat it as banned and check the current annual Prohibited List directly.[6](https://peptidevox.com/#r6)

**Bottom line.** Pinealon (EDR / Glu-Asp-Arg) is a genuinely interesting ultrashort peptide with a coherent preclinical antioxidant-neuroprotection story — dose-dependent ROS suppression, anti-apoptotic effects, SOD2/GPX1 upregulation, dendritic-spine preservation and improved maze learning in rodents — plus a provocative but largely unverified "binds DNA to regulate genes" mechanism. What is proven is cell and rodent neuroprotection (Grade C); what is hyped is human cognition, anti-aging and Alzheimer's benefit (Grade D). Nearly all data come from a single research group, the DNA-binding mechanism is unconfirmed, and there is no human PK or formal safety dataset. For an athlete it is effectively prohibited under S0; for everyone else it remains an experimental compound that is not legally a medicine in the US or EU as of 2026. Regulatory facts here should be re-verified against primary FDA and WADA sources before relying on them.

---
Source: https://peptidevox.com/peptide-encyclopedia/elcatonin
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt